Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Big Pharma Split's FCF Margin % or its related term are showing as below:
FRA:XN4'
s FCF Margin % Range Over the Past 10 Years
Min: -7605.41 Med: 30.4 Max: 3862.54
Current: -15.64
During the past 9 years, the highest FCF Margin % of Big Pharma Split was 3862.54%. The lowest was -7605.41%. And the median was 30.40%.
FRA:XN4's FCF Margin % is not ranked
in the Asset Management industry.
Industry Median: 14.215
vs FRA:XN4: -15.64
Big Pharma Split FCF Margin % Related Terms
Big Pharma Split FCF Margin % Historical Data
* Premium members only.
The historical data trend for Big Pharma Split's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, Big Pharma Split's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Big Pharma Split FCF Margin % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Big Pharma Split's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Big Pharma Split's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Big Pharma Split (FRA:XN4) has a FCF Margin % of -32.12% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Big Pharma Split and its competitors.
Is Big Pharma Split's FCF Margin % too high?
Big Pharma Split's current FCF Margin % is -32.12%. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's FCF Margin % compare to BLK and BX?
Big Pharma Split's FCF Margin % of -32.12% can be compared against companies in the Asset Management industry. The industry median FCF Margin % is 14.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for an Asset Management company?
The median FCF Margin % among Asset Management companies is 14.22, based on 1,456 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Big Pharma Split and its competitors. For the Asset Management industry, the median FCF Margin % is 14.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Big Pharma Split's current FCF Margin % is -32.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (FRA:XN4) has a current FCF Margin % of -32.12%. The stock's GF Value™ is €1.07, compared to a current price of €6.90 — trading 544.9% above its estimated fair value. The current FCF Margin % is -32.12%. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Big Pharma Split (FRA:XN4), the current FCF Margin % is -32.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Big Pharma Split (FRA:XN4) Overvalued in 2026?
Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued.
The current stock price of €6.90 is trading 544.9% above its estimated GF Value™ of €1.07.
Key valuation signals for FRA:XN4:
FCF Margin %: -32.12%
GF Value™: €1.07 vs. price of €6.90 (544.9% above fair value)
No single metric tells the full story. See the FRA:XN4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score
Get the complete analysis for FRA:XN4
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:XN4 has been successfully added to your 
